GRAIL CFO Sells Over 9,500 Shares

Aaron Freidin, the CFO of biotech firm GRAIL, sold nearly $500,000 worth of company stock.

Mar. 4, 2026 at 12:36pm

Got story updates? Submit your updates here. ›

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 9,573 shares of the company's stock on Monday, March 2nd. The shares were sold at an average price of $50.17, resulting in a total transaction value of $480,277.41. Following the sale, Freidin still owns 309,622 shares of the company, valued at approximately $15.5 million.

Why it matters

Insider transactions, such as stock sales by company executives, can provide insights into a firm's financial health and management's confidence in the business. The sale by GRAIL's CFO may signal potential concerns about the company's near-term prospects, despite its innovative cancer detection technology.

The details

Freidin's stock sale represented a 3% decrease in his position in GRAIL. The company, which went public in 2020, is focused on developing a multi-cancer early detection blood test called Galleri. GRAIL reported a net loss of $2.44 per share for the fourth quarter of 2025, though it exceeded analysts' expectations.

  • The stock sale occurred on Monday, March 2, 2026.
  • GRAIL reported its Q4 2025 earnings on Thursday, February 19, 2026.

The players

Aaron Freidin

The Chief Financial Officer of GRAIL, Inc.

GRAIL, Inc.

A biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test.

Got photos? Submit your photos here. ›

The takeaway

The stock sale by GRAIL's CFO raises questions about the company's near-term outlook, despite its promising cancer detection technology. Investors will be closely watching for any further insider transactions and the company's future financial performance as it continues to develop its Galleri test.